WHAT IS CLAIMED:

1. A compound comprising a modified oligonucleotide 14 to 30 linked nucleosides in length having

i) a nucleobase sequence comprising at least 14 contiguous nucleobases of SEQ ID NO: 2879;

ii) a nucleobase sequence comprising a portion of at least 14 contiguous nucleobases 100% complementary to an equal length portion of nucleobases 87,359-90,915; 90,968-97,263; 83,573-87,287; 3,404-44,737; 97,378-104,979; 81,061-81,199; or 116,048-116,903 of SEQ ID NO: 1,

iii) a nucleobase sequence complementary to intron 12, intron 13, intron 11, intron 1, intron 14, exon 10, or the 3'-UTR of a human DNM2 pre-mRNA or human DNM2 mRNA, or

iv) a nucleobase sequence comprising at least 12, at least 13, at least 14, or at least 15 contiguous nucleobases of any one of the nucleobase sequences of SEQ ID NOs: 7-3134.

2. The compound of claim 1, wherein the modified oligonucleotide has a nucleobase sequence consisting of any one of SEQ ID NOs: 2879, 2123, 2189, 2160, 3056, 2453, or 2232.

3. The compound or claim 1 or 2, wherein the modified oligonucleotide comprises:

a gap segment consisting of 8-12 linked 2'-deoxynucleosides, preferably 10 linked 2'-deoxynucleosides;

a 5' wing segment consisting of 1-7 linked nucleosides, preferably 3 linked nucleosides; and

a 3' wing segment consisting of 1-7 linked nucleosides, preferably 3 linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment and wherein each terminal wing nucleoside comprises a modified sugar.

4. The compound of claim 1, wherein the modified oligonucleotide is at least 80%, 85%, 90%, 95% or 100% complementary to any of SEQ ID NOs: 1, 2, 3, or 3135.

5. The compound of any one of claims 1 to 4, wherein the modified oligonucleotide comprises at least one modified internucleoside linkage, preferably a phosphorothioate internucleoside linkage.

6. The compound of any one of claims 1 to 5, wherein the modified oligonucleotide comprises at least one bicyclic sugar, preferably selected from the group consisting of LNA, ENA, and cEt.

7. The compound of any one of claims 1-6, wherein the modified oligonucleotide comprises at least one 5-methylcytosine.

8. The compound of any one of claims 1-7, wherein the compound is single-stranded.

9. The compound of any one of claims 1-7, wherein the compound is double-stranded.

10. The compound of any one of claims 1-9, wherein the modified oligonucleotide consists of 16 to 20 linked nucleosides.

11. A compound comprising a modified oligonucleotide according to the following formula: Gks Tks Tks Tds Ads Tds Tds Ads Tds Ads Gds Gds Gds mCks Tks Tk; wherein,

A = an adenine,

mC = a 5-methylcytosine

G = a guanine,

T = a thymine,

k = a cEt sugar moiety,


d = a 2'-deoxyribosyl sugar moiety, and

s = a phosphorothioate internucleoside linkage.

12. The compound of any one of claims 1-11 comprising a conjugate group, preferably wherein

the compound consists of the modified oligonucleotide and the conjugate group.

13. A compound according to the following formula:



[SEQ ID NO: 2879] or a salt thereof.

14. A compound consisting of a pharmaceutically acceptable salt form of any one of the compounds of claims 1-13, preferably wherein the pharmaceutically acceptable salt is a sodium salt or a potassium salt.

15. A chirally enriched population of the compounds of any one of claims 1-14, wherein the population is enriched for modified oligonucleotides comprising at least one particular phosphorothioate internucleoside linkage having a particular stereochemical configuration.

16. A pharmaceutical composition comprising compound of any one of claims 1-14 or the population of compounds of claim 15 and at least one pharmaceutically acceptable diluent or carrier.

17. The compound of any one of claims 1-14, the population of compounds of claim 15 or the pharmaceutical composition of claim 16, for use in therapy.

18. The compound of any one of claims 1-14, the population of claim 15, or the pharmaceutical composition of claim 16, for use in treating, preventing, or ameliorating centronuclear myopathy, Duchenne Muscular Dystrophy, or Charcot-Marie Tooth disease, preferably wherein the disease is X-linked myotubular myopathy, autosomal recessive centronuclear myopathy, or autosomal dominant centronuclear myopathy, wherein more preferably, the disease is associated with a mutation in at least one gene selected from among MTM1, BIN1, and DNM2.

19. An *in vitro* method of inhibiting expression of DNM2 in a cell comprising contacting the cell with a single-stranded compound comprising a modified oligonucleotide 100% complementary to exon 10, an intron, or the 3'-UTR of a DNM2 nucleic acid transcript, thereby inhibiting expression of DNM2 in the cell.